RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?
RedHill Biopharma Ltd. (NASDAQ:RDHL) has acquired the commercialization rights to two gastrointestinal products from Ferring Pharmaceuticals. The $12 million upfront payment comes from the proceeds of Talicia divestiture. In addition to the upfront, RedHill Biopharma will receive tiered royalties between 5% and 20% of net sales, as well as potential milestone-based payments.
The agreement covers Rebyota and Clenpiq, with the latter having already generated $37.5 million in combined US net sales in 2025. The structure limits RedHill Biopharma's upfront spending while relying on royalties, inventory funding, and supplier performance for economics.
Written by urgent.news from Yahoo Finance's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
